Live feed02:30:00·3mPRReleasevia QuantisnowEnhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 TrialByQuantisnow·Wall Street's wire, on your screen.AZN· AstraZeneca PLCHealth Care
